Irinotecan

Sandra D’Angelo, MD, discussed a clinical trial on trabectedin in combination with low-dose irinotecan in Ewing sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with nab-paclitaxel and gemcitabine as initial treatment for patients with metastatic pancreatic ductal adenocarcinoma, study results showed.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the TRIPLETE trial, which she said showed no improvement when irinotecan was added to FOLFOX panitumumab in patients with mostly unresectable RAS and BRAF wild-type left-sided metastatic colorectal cancer.

A recent study showed that neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy extended survival in patients with borderline resectable pancreatic cancer.

The FDA granted fast track designation to liposomal irinotecan as part of a first-line combination for the treatment of adults with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.

The addition of dinutuximab to irinotecan failed to extend OS among patients with relapsed or refractory small cell lung cancer, according to topline data from a randomized phase 2/phase 3 trial released by the agent’s manufacturer.